Chronic Liver Disease Market to Witness Growth by 2032, Estimates DelveInsight | Companies- Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, expected to boost the market

DelveInsight's "Chronic Liver Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Liver Disease, historical and forecasted epidemiology as well as the Chronic Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Liver Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Liver Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Liver Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Liver Disease market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease: An Overview

As mentioned, a key challenge is that a liver biopsy can confirm the diagnosis of Chronic Liver Disease, which is invasive. Some other diseases may mimic the presentation of Chronic Liver Disease, making differential diagnosis necessary. Concerning the above, the absence of a treatment portfolio indicates diagnostic loopholes.
In the absence of any existing FDA-approved medications for the treatment of NAFLD/NASH, the mainstay of management continues to be dietary and other lifestyle changes tailored to the individual patient. The current treatments for this illness are not keeping up with advances in medical research and technology. Discovering novel and effective medicines that address the intricacies of chronic liver disease and improve patient outcomes is critical. The management of this illness can be improvised to better the quality of life for those living with chronic liver disease by embracing innovative treatment methods. Numerous medications have been added to the pipeline of novel therapies, increasing the promise of successful treatment of NASH. In the meantime, first-line drugs such as vitamin E and pioglitazone continue to serve their purpose in carefully selected patients, with or without diabetes.
Bearing in mind the characteristics discussed, it is the need of the hour to introduce diagnostic procedures that are gold standard non-invasively along with the forecast period treatment approvals as multiple drugs in the hepatology space have already entered the "Hepatology graveyard" accrediting to after failed studies.

Learn more about Chronic Liver Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Market

The management of patients with Chronic Liver Disease depends on the stage of the liver disease. Liver fibrosis and cirrhosis result from underlying conditions like NASH, ALD, CHB, CHC, and others which progress to a stage of severity that becomes chronic due to the lack of standard treatment.

As per the guidelines from the American Liver Foundation, without any branded approvals, management of underlying comorbidity that is central to treating NASH and related fibrosis is of utmost importance. Various off-label therapies are used to manage Chronic Liver Disease complications, such as vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), anti-hyperlipidemic agents (e.g., gemfibrozil), pentoxifylline, and UDCA.

According to DelveInsight, the Chronic Liver Disease market is expected to witness considerable changes in the 7MM during the study period 2019-2032.

Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Epidemiology Insights
According to Ginès et al. (2016), the prevalence of increased liver stiffness in the general adult population without previously known liver diseases is high (between 5.6% and 7.5%). The prevalence among individuals with risk factors is much higher (between 18% and 27%), which suggests an alarmingly high prevalence of chronic liver diseases in the general population.
According to Axley et al. (2018), the fibrosis stages range from F0 to F4. Advanced liver fibrosis is an important predictor of liver disease progression and mortality, and current guidelines recommend screening for complications of cirrhosis once patients develop F3 fibrosis.
According to Ginès et al. (2016), studies have shown that 6-7% of adults without known liver disease have liver fibrosis, mostly associated with non-alcoholic fatty liver disease.


Explore more about Chronic Liver Disease Epidemiology at: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Liver Disease Drugs Chapters

Chronic Liver Disease Drug Chapters
Emerging Drugs
While several late-staged and early-staged therapeutics are under development, the pharmaceutical product pipeline of Chronic Liver Disease is prolific. It includes leading pharma players in the pursuit of cracking the code in the protracted hepatology space.
Semaglutide: Novo Nordisk
Semaglutide is a selective GLP-1 receptor agonist given once daily, subcutaneously, for the treatment of non-alcoholic steatohepatitis (NASH). Based on studies, the development of Semaglutide in NASH is very much on track. It is currently in Phase III of its clinical development with a promise for closer to a solution that can be a potential launch in the hepatology space during the forecast period.
Resmetirom (formerly MGL-3196): Madrigal Pharmaceuticals
Madrigal's main attraction was its lead NASH compound, MGL-3196, a once-daily pill for fatty liver disease in-licensed from Roche, Resmetirom (formerly MGL-3196), a Phase III molecule that is a first-in-class, oral, once-daily formulation to target F2 and F3, and F4 stage patients. The company plans to file subpart H-accelerated approval for sooner entry into the market. This filling will be done based on recently published results; later, it will be continued by full NDA submission. Resmetirom also has FTD, which will help shorten the filling period. If all goes as planned, Resmetirom can be a potential launch in the hepatology space during the forecast period.

Chronic Liver Disease Pipeline Development Activities

The Chronic Liver Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chronic Liver Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Chronic Liver Disease pipeline development activities at: https://www.delveinsight.com/sample-request/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chronic Liver Disease Therapeutics Assessment

Major key companies such as Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, and others are working proactively in the Chronic Liver Disease Therapeutics market to develop novel therapies which will drive the Chronic Liver Disease treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Chronic Liver Disease Report Key Insights

1. Chronic Liver Disease Patient Population
2. Chronic Liver Disease Market Size and Trends
3. Key Cross Competition in the Chronic Liver Disease Market
4. Chronic Liver Disease Market Dynamics (Key Drivers and Barriers)
5. Chronic Liver Disease Market Opportunities
6. Chronic Liver Disease Therapeutic Approaches
7. Chronic Liver Disease Pipeline Analysis
8. Chronic Liver Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Chronic Liver Disease Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Chronic Liver Disease Competitive Intelligence Analysis
4. Chronic Liver Disease Market Overview at a Glance
5. Chronic Liver Disease Disease Background and Overview
6. Chronic Liver Disease Patient Journey
7. Chronic Liver Disease Epidemiology and Patient Population
8. Chronic Liver Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Liver Disease Unmet Needs
10. Key Endpoints of Chronic Liver Disease Treatment
11. Chronic Liver Disease Marketed Products
12. Chronic Liver Disease Emerging Therapies
13. Chronic Liver Disease Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Liver Disease Market Outlook (7 major markets)
16. Chronic Liver Disease Access and Reimbursement Overview
17. KOL Views on the Chronic Liver Disease Market
18. Chronic Liver Disease Market Drivers
19. Chronic Liver Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Chronic Liver Disease Market report here: https://www.delveinsight.com/report-store/chronic-liver-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.